Sun Pharmaceutical Industries, India's leading drugmaker by revenue, has received regulatory approval to manufacture and sell a generic version of the blockbuster weight-loss drug Wegovy in the country.
Generic Semaglutide Launch Details
The company will introduce generic semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic, under the brand name Noveltreat. This rollout is planned once the semaglutide patent expires in March 2026.
India's Push into Weight Loss Market
Indian generic manufacturers are accelerating efforts to enter the rapidly growing weight-loss sector ahead of the patent deadline.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Sun Pharma is the second Indian drugmaker to gain approval for generic semaglutide. It follows Dr. Reddy's Laboratories, which recently announced approval for a generic version of the diabetes drug Ozempic.
Key Facts on Semaglutide
- Wegovy and Ozempic share the same active ingredient: semaglutide.
- Ozempic is approved for diabetes but often used off-label for weight loss due to its appetite-suppressing effects.
This development promises more accessible GLP-1 medications for weight management in India.
